Nasdaq Akba News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Nasdaq akba. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Nasdaq Akba Today - Breaking & Trending Today
StockNews.com lowered shares of Akebia Therapeutics (NASDAQ:AKBA – Free Report) from a buy rating to a hold rating in a research report released on Monday morning. Separately, HC Wainwright raised their target price on Akebia Therapeutics from $5.00 to $6.00 and gave the company a buy rating in a report on Thursday, March 28th. Check […] ....
Akebia Therapeutics, Inc. (NASDAQ:AKBA – Get Free Report) SVP Steven Keith Burke sold 24,311 shares of the business’s stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $1.68, for a total transaction of $40,842.48. Following the completion of the sale, the senior vice president now owns 711,376 […] ....
Akebia Therapeutics (NASDAQ:AKBA – Get Free Report) is set to announce its earnings results on Wednesday, November 1st. Akebia Therapeutics (NASDAQ:AKBA – Get Free Report) last announced its earnings results on Friday, August 25th. The biopharmaceutical company reported ($0.06) EPS for the quarter, missing the consensus estimate of ($0.03) by ($0.03). The firm had revenue […] ....
Akebia Therapeutics, Inc. (NASDAQ:AKBA – Free Report) – Equities research analysts at HC Wainwright lowered their Q3 2023 earnings estimates for shares of Akebia Therapeutics in a research report issued to clients and investors on Wednesday, September 27th. HC Wainwright analyst E. Arce now forecasts that the biopharmaceutical company will earn ($0.07) per share for […] ....
Akebia Therapeutics (NASDAQ:AKBA – Get Free Report) released its quarterly earnings results on Friday. The biopharmaceutical company reported ($0.06) EPS for the quarter, missing the consensus estimate of ($0.03) by ($0.03), MarketWatch Earnings reports. Akebia Therapeutics had a negative net margin of 20.79% and a negative return on equity of 235.17%. During the same quarter […] ....